{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-023155","form_type":"8-K","ticker":null,"cik":"0001745020","company_name":"Theseus Pharmaceuticals, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.370996+00:00","generated_at":"2026-06-06T02:29:14.914955+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Theseus acquired by Concentra for $4.05/share + CVR; delisting from Nasdaq","bullets":["Tender offer closed Feb 13 with 83.3% (37,211,244 shares) tendered; merger completed Feb 14.","Stockholders received $4.05 cash per share plus one CVR representing potential future payments.","Board of directors resigned; new directors and officers include Kevin Tang (CEO) and Michael Hearne (CFO).","Company requested delisting from Nasdaq and intends to deregister under Section 12(g) of Exchange Act.","Controlled equity offering agreement with Cantor Fitzgerald terminated effective as of closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-023155","json":"https://secwatch.observer/filing/0001104659-24-023155.json","markdown":"https://secwatch.observer/filing/0001104659-24-023155.md","text":"https://secwatch.observer/filing/0001104659-24-023155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/tm246030d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:29:14.914955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b2e0c3b10","claim":"Steven Stein resigned as Director at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"each of Iain Dukes, Carl Gordon, Donald Hayden, Michael Rome, Steven Stein, Kathy Yi and Bradford Dahms resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"397706e50c","claim":"Stew Kroll was appointed as Chief Development Officer at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"Stew Kroll, serving as Chief Development Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"},{"claim_id":"50ba68ebc5","claim":"Thomas Wei was appointed as Chief Business Officer at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"Thomas Wei, serving as Chief Business Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"90b08dc001","claim":"Carl Gordon resigned as Director at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"each of Iain Dukes, Carl Gordon, Donald Hayden, Michael Rome, Steven Stein, Kathy Yi and Bradford Dahms resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9e7d16deab","claim":"Michael Hearne was appointed as Chief Financial Officer at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"Michael Hearne, serving as Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"bbf51ce14f","claim":"Iain Dukes resigned as Director at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"each of Iain Dukes, Carl Gordon, Donald Hayden, Michael Rome, Steven Stein, Kathy Yi and Bradford Dahms resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c05b5a171c","claim":"Bradford Dahms resigned as Director at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"each of Iain Dukes, Carl Gordon, Donald Hayden, Michael Rome, Steven Stein, Kathy Yi and Bradford Dahms resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ccd07325ac","claim":"Kevin Tang was appointed as Director at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d88429e1f0","claim":"Ryan Cole was appointed as Chief Operating Officer at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"Ryan Cole, serving as Chief Operating Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"dc9e7e1aa1","claim":"Kevin Tang was appointed as Chief Executive Officer at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"Kevin Tang, serving as Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e09c0b4dd6","claim":"Kathy Yi resigned as Director at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"each of Iain Dukes, Carl Gordon, Donald Hayden, Michael Rome, Steven Stein, Kathy Yi and Bradford Dahms resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ee8704f675","claim":"Donald Hayden resigned as Director at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"each of Iain Dukes, Carl Gordon, Donald Hayden, Michael Rome, Steven Stein, Kathy Yi and Bradford Dahms resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f4b2162e14","claim":"Michael Rome resigned as Director at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"each of Iain Dukes, Carl Gordon, Donald Hayden, Michael Rome, Steven Stein, Kathy Yi and Bradford Dahms resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"47bb853229c132cd28d62424153fc2a5e34c77e3","claim":"Theseus Pharmaceuticals, Inc.: Bylaws amended and restated in their entirety in connection with the merger.","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth on Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"f80061435e9d561fc587d0c81bef12c5a086e244","claim":"Theseus Pharmaceuticals, Inc.: Certificate of incorporation amended and restated in its entirety in connection with the merger.","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth on Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"66f115d1921b7ac5b6681ca259c06b3f50f03989","claim":"Theseus Pharmaceuticals, Inc. underwent a change of control involving Concentra Biosciences, LLC for $4.05 in cash per Share, plus one non-transferable contractual contingent value right per Share (closed 2024-02-14).","evidence_excerpt":"2024, Merger Sub completed a tender offer to purchase all of the C ompany’s outstanding shares of common stock, par value $0.0001 per share (the “ Shares ”), in exchange for (i) $4.05 in cash per Share (the “ Cash Amount ”), plus (ii) one non-transferable contractual contingent value right per Share (each, a “ CVR ” and each CVR together with the Cash Amount,","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Concentra Biosciences, LLC"},{"label":"Consideration","value":"$4.05 in cash per Share, plus one non-transferable contractual contingent value right per Share"},{"label":"Closing","value":"2024-02-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}